Reciprocal Impact of Molnupiravir and Favipiravir Monocomponents of the Combination Drug on Each Other's Pharmacokinetics in a Phase I Clinical Trial

Reciprocal Impact of Molnupiravir and Favipiravir Monocomponents of the Combination Drug on Each Other's Pharmacokinetics in a Phase I Clinical Trial

Introduction. COVID-19 (Coronavirus disease 2019) almost 4 years after he start of the pandemic is still a significant public health problem. SARS-CoV-2 (Severe acute respiratory syndrome coronavirus 2) that causes COVID-19 continues to mutate and spread throughout the world. Molnupiravir and favipi...

Full description

Saved in:
Bibliographic Details
Main Authors: T. N. Komarov, K. K. Karnakova, N. S. Bagaeva, O. A. Archakova, M. O. Popova, V. S. Shcherbakova, K. Ya. Zaslavskaya, P. A. Bely, I. E. Shohin
Format: Article
Language:Russian
Published: LLC Center of Pharmaceutical Analytics (LLC «CPHA») 2024-03-01
Series:Разработка и регистрация лекарственных средств
Subjects:
molnupiravir
favipiravir
covid-19
pharmacokinetics
Online Access:https://www.pharmjournal.ru/jour/article/view/1770
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.pharmjournal.ru/jour/article/view/1770

Similar Items